Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Alabama › Birmingham
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Birmingham, AL keessatti
Qorannoo 22 Kansara Qara'a Non-Small Cell f Birmingham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Namoota walitti qabaa jiraSadarkaa 3
- Central Alabama Research ( Site 0108), Birmingham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Namoota walitti qabaa jiraSadarkaa 3
- Alabama Oncology, Birmingham
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Alabama Oncology, St Vincent's Birmingham, Birmingham
- Alabama Oncology, Brookwood, Birmingham
- Alabama Oncology, Princeton, Birmingham
- fi 5 dabalataa
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham, Birmingham
Pan-tumor MRD Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Alabama Oncology, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Namoota walitti qabaa jiraSadarkaa 3
- Local Institution - 0347, Birmingham
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- UAB Medicine - UAB Hospital, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Namoota walitti qabaa jiraQorannoo ilaalaa
- University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Alabama, Birmingham
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Uni of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- fi 1 dabalataa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Namoota walitti qabaa jiraSadarkaa 3
- Central Alabama Research, Birmingham
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham, Birmingham
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Namoota walitti qabaa jiraSadarkaa 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Namoota walitti qabaa jira
- University of Alabama at Birmingham, Birmingham
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Namoota walitti qabaa jiraSadarkaa 2
- The University of Alabama at Birmingham Hospital, Birmingham
GEMINI-NSCLC: NSCLC Biomarker Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Alabama Oncology, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Birmingham
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Birmingham keessatti
- Saree (Gosoota Hunda)Qorannoo 31
- Saree OljooQorannoo 24
- Kansarii OvariiQorannoo 23
- ObesityQorannoo 23
- Leukemia Myeloidii HamaaQorannoo 21
- Myeloma Baay’eeQorannoo 18
- COPDQorannoo 17
- Dhibee Onneessaa fi DhiigaQorannoo 17
- Sukkaraa Gosa 2Qorannoo 16
- Kansa EndometiriyaaliiQorannoo 16
- Baayyee UlfaataaQorannoo 16
- Faayibrosisis KistiiqiiQorannoo 16
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.